(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 March 2014 (13.03.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/037373 A1

(51) International Patent Classification:
C07K 14/50 (2006.01) *A61K 38/18* (2006.01)
C07K 14/605 (2006.01) *A61K 38/26* (2006.01)

(21) International Application Number:
PCT/EP2013/068239

(22) International Filing Date:
4 September 2013 (04.09.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12306072.5 7 September 2012 (07.09.2012) EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) Inventors: **BOSCHEINEN, Oliver**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **DREYER, Matthias**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **HABERMANN, Paul**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SCHAEFER, Hans-Ludwig**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SOMMERFELD, Mark**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **LANGER, Thomas**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agent: **TIMMERBEIL, Björn**; c/o Sanofi-Aventis Deutschland GmbH, Patents Germany, Industriepark Höchst, Geb. K703, 65926 Frankfurt am Main (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/037373 A1

(54) **Title**: FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME

(57) **Abstract**: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.